An interventional study of Prostate radical radiotherapy in Prostate Cancer, sponsored by Royal Marsden NHS Foundation Trust. Recruiting at 3 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Royal Marsden NHS Foundation Trust · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust — 8 open to participants now, 10 under way, 1 of them phase 3. Prostatic Neoplasms · Royal Marsden NHS Foundation Trust.
Among the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, and was the 17th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →8 of the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 2 countries. Recruiting first, the newest first:
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18–100 · Men only · Healthy volunteers
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Men only
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only · Healthy volunteers
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 3
First in 2000; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 54 is close to the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 81 across the 14 interventional studies, 100 across the 7 observational. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Royal Marsden NHS Foundation Trust is the lead sponsor of 275 studies on the registry; 54 are open to participants now.
4 of the studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06638541Royal Marsden NHS Foundation TrustDose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions | 2027-01-01 |
| NCT06019676Royal Marsden NHS Foundation TrustImpact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients | 2027-04-01 |
| NCT07870707Royal Marsden NHS Foundation TrustProstate Cancer in UK Prisons: A Retrospective Data Analysis | 2027-08-03 |
| NCT07741929Royal Marsden NHS Foundation TrustPatient and Provider Perspectives on Genetic Risk Profiling | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, from their registry updates:
This tab as a report to print or save as PDF → With an account.
DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT). All radiotherapy will be delivered in two fractions (sessions) on an MR Linac using daily adaptation. Men will either receive uniform dose radiotherapy or de-escalated dose radiotherapy. The primary endpoint is acute GU CTCAE v5 grade 2+ toxicity. It will also look at late toxicity, patient-reported outcome measures and PSA control.
54 patients meeting inclusion criteria will be randomised between two arms. Arm 1 (Uniform dose) will receive 27 Gy in 2 fractions to the whole prostate + seminal vesicles (SV), the CTV, with 0 mm CTV-PTV margin. Arm 2 (De-escalated dose) will use two dose levels: The benign prostate (on MRI) will receive 20 Gy in 2 fractions with a 0mm PTV margin. The intraprostatic tumour mass(es) as seen on MRI will receive 27 Gy in 2 fractions. A 4mm GTV-PTV margin will be added to the MR visible tumour to form PTV 27Gy. The primary endpoint is emergent acute GU CTCAE v5 Grade 2+ toxicity, recorded within 3 months of completing radiotherapy. Secondary endpoints are CT CAE v5 acute GI toxicity, late toxicity, patient-reported outcome measures (PROMs) (EPIC-26, IPSS, and IIEF-5) at 4 and 12 weeks, 6 months, 1 and 2 years post treatment, PSA control and kinetics
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1 (Uniform dose) will receive 27 Gy in 2 fractions to the whole prostate + seminal vesicles (SV), the CTV, with 0 mm CTV-PTV margin.
Radiation: Prostate radical radiotherapy
Arm 2 (De-escalated dose) will use two dose levels: The benign prostate (on MRI) will receive 20 Gy in 2 fractions with a 0mm PTV margin. The intraprostatic tumour mass(es) as seen on MRI will receive 27 Gy in 2 fractions. A 4mm GTV-PTV margin will be added to the MR visible tumour to form PTV 27Gy.
Radiation: Prostate radical radiotherapy
Radiation: De-escalated radiotherapy to be delivered on the Elekta Unity MR-linac
Acute GU toxicity
To describe the absolute risk and relative risk reduction of acute genitourinary (GU) toxicity (CTCAE v5) when delivering de-escalated two fraction prostate SBRT compared to uniform dose two fraction prostate stereotactic body radiotherapy (SBRT) for intermediate risk prostate cancer.
Time frame: 12 weeks
Acute Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) toxicity
To describe the absolute and relative risk of toxicity
Time frame: Baseline, last fraction, week 2, 4 and 12
Late Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) toxicity
To describe the absolute and relative risk of toxicity
Time frame: Month 6, 12, 24
Feasibility of radiation delivery
Feasibility- estimate percentage of fractions interrupted due to patient discomfort
Time frame: At time of treatment
Dosimetry
Dosimetry- estimate the accumulated dose differences between the de-escalated and uniform dose delivery
Time frame: At time of treatment
Patient reported outcome measures
To assess baseline, acute and late International Prostate Symptom Score (IPSS). IPSS ranges from 0 to 35. Lower scores are better: A lower score indicates fewer or less severe urinary symptoms, while a higher score suggests more severe symptoms.
Time frame: Baseline, last fraction of treatment, week 2, 4 and 12, 6 months, 1 and 2 years post treatment.
Patient reported outcome measures
Expanded Prostate Cancer Index Composite Short Form (EPIC-26). EPIC-26 scores are transformed to a 0-100 scale for each domain.The questionnaire usually covers urinary incontinence, urinary irritative/obstructive symptoms, bowel, sexual, and hormonal functions. Higher scores represent better health-related quality of life.
Time frame: Baseline, 4 and 12 weeks, 6 months, 1 and 2 years post treatment.
Patient reported outcome measures
International Index of Erectile Function-5 (IIEF-5). The IIEF-5 score ranges from 5 to 25. Higher scores are better: A higher score indicates better erectile function, while a lower score suggests more severe erectile dysfunction.
Time frame: Baseline, 6 months, 1 and 2 years post treatment.
PSA kinetics
To assess biochemical relapse-free survival at 2 years
Time frame: Baseline (pre ADT), week 12, month 6, and 1 and 2 years post treatment
Plan to share: Yes — It is intended that data will be shared within the MOMENTUM collaboration, between centres delivering treatment in the same way as DESTINATION2. Pseudonymised data will be stored within MOMENTUM for at least 5 years. Storage will be cloud based and as the treating centre we will have free access to the data and control over who else can assess it.
Time frame: 5 years
Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 23 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Marsden NHS Foundation Trust →